Scancell (SCLP) Competitors

Scancell (LON:SCLP) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Is SCLP or OXB more profitable?

Scancell has a net margin of 0.00% compared to Oxford Biomedica's net margin of -145.98%. Scancell's return on equity of 98.74% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	N/A	98.74%	-45.28%
Oxford Biomedica	-145.98%	-202.50%	-12.67%

Which has more risk and volatility, SCLP or OXB?

Scancell has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Oxford Biomedica has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Do analysts prefer SCLP or OXB?

Oxford Biomedica has a consensus target price of GBX 380, suggesting a potential upside of 17.47%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, analysts plainly believe Oxford Biomedica is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the MarketBeat Community favor SCLP or OXB?

Oxford Biomedica received 172 more outperform votes than Scancell when rated by MarketBeat users. However, 74.50% of users gave Scancell an outperform vote while only 66.73% of users gave Oxford Biomedica an outperform vote.

Company	Underperform	Outperform
Scancell	Outperform Votes 187 74.50%	Underperform Votes 64 25.50%
Oxford Biomedica	Outperform Votes 359 66.73%	Underperform Votes 179 33.27%

Do institutionals & insiders hold more shares of SCLP or OXB?

46.5% of Scancell shares are owned by institutional investors. Comparatively, 64.1% of Oxford Biomedica shares are owned by institutional investors. 5.0% of Scancell shares are owned by company insiders. Comparatively, 21.2% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has preferable earnings & valuation, SCLP or OXB?

Scancell has higher earnings, but lower revenue than Oxford Biomedica. Scancell is trading at a lower price-to-earnings ratio than Oxford Biomedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	N/A	N/A	-£6.75M	-£0.65	-15.18
Oxford Biomedica	£98.31M	3.50	-£143.51M	-£134.59	-2.40

Does the media refer more to SCLP or OXB?

In the previous week, Scancell and Scancell both had 2 articles in the media. Scancell's average media sentiment score of 0.71 beat Oxford Biomedica's score of 0.00 indicating that Scancell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scancell	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oxford Biomedica	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Oxford Biomedica beats Scancell on 9 of the 15 factors compared between the two stocks.